Clostridium difficile infection (CDI) is facilitated by
NAME

Bezlotoxumab (Zinplava)
APPROVED FOR
Adjuvant therapy to reduce recurrence of CDI in high-risk patients receiving antimicrobial therapy for CDI
TYPE
Bezlotoxumab is a fully human monoclonal IgG 1 antibody
MOLECULAR TARGETS
TcdB, a protein toxin produced by C. difficile that glycosylates host Rho family GTPases
CELLULAR TARGETS
No demonstrated cellular targets; presumably protects host cells from intoxication with TcdB
EFFECTS ON TARGETS
Bezlotoxumab binds to TcdB and inhibits its ability to bind to its cellular surface receptors. Bezlotoxumab is proposed to bind to the N-terminal domain (putative cell-binding region) of TcdB. Antibody-bound TcdB exhibits reduced cell entry and decreased subsequent glycosylation of the Rho family of GTPases, which are the host cell targets of TcdB. 
